Symbicort Aerosol
Product Images NDC 0186-0372

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Symbicort (NDC 0186-0372). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure1bodytext)

A line graph depicting percent change from baseline in predicted FEV1 over 12 weeks with different treatment groups. The x-axis represents time in weeks, and the y-axis shows percent change. Several lines plot FEV1 changes for SYMBICORT 160/4.5 mcg, Budesonide 160 mcg, Formoterol 4.5 mcg, Budesonide 160 mcg plus Formoterol 4.5 mcg, and placebo.*

FDA Label Image

Figure 2 (Figure2bodytext)

A line graph showing percent change from baseline in predose FEV1 over 12 weeks for four treatment groups: SYMBICORT 80/4.5 mcg, Budesonide 80 mcg, Formoterol 4.5 mcg, and placebo. The x-axis represents weeks (0, 2, 6, 12) and the y-axis shows percent change. SYMBICORT shows the highest improvement, followed by Budesonide, Formoterol, and placebo. Sample sizes for each group at each time point are listed below the graph.*

FDA Label Image

Figure 3 (Figure3bodytext)

A line graph depicting the percent change from baseline in FEV1 over 12 hours for different inhalation treatments, including SYMBICORT 160/4.5 mcg, Budesonide 160 mcg, Formoterol 4.5 mcg, and their combination, compared to placebo. The x-axis shows time in hours, and the y-axis shows the percent change from baseline.*

FDA Label Image

Figure 4 (Figure4bodytext)

A line graph showing percent change from baseline in FEV1 over 12 hours comparing SYMBICORT (160/4.5 mcg), budesonide (160 mcg), formoterol (4.5 mcg), budesonide plus formoterol, and placebo. The x-axis represents time in hours, and the y-axis shows percent change in FEV1. SYMBICORT and formoterol show higher improvements compared to budesonide and placebo.*

FDA Label Image

Figure 5 (Figure5bodytext)

A line graph showing the change from baseline in 1-hour post-dose FEV1 (L) over 12 weeks. It compares two treatments: SYMBICORT 80/4.5 mcg (two inhalations twice daily) and Budesonide 80 mcg (two inhalations twice daily). The graph includes data points and the number of patients assessed at Weeks 0, 1, 2, 4, 8, and 12 for each treatment group.*

FDA Label Image

Figure 6 (Figure6bodytext)

A line graph showing percent change from baseline in pre-dose FEV1 over six months with different treatment groups for SYMBICORT 160/4.5 mcg aerosol, Budesonide 160 mcg, Formoterol 4.5 mcg, their combination, and placebo. The x-axis represents months of treatment, and the y-axis shows percent change in FEV1. Data points include sample sizes at each time point for each group, illustrating lung function changes over time.*

FDA Label Image

Figure 7 (Figure7bodytext)

A line graph showing percent change from baseline in 1-hour post-dose FEV1 over 6 months of treatment for SYMBICORT and comparator treatments. The graph includes data for SYMBICORT MDI 160/4.5 mcg, budesonide 160 mcg, formoterol 4.5 mcg, budesonide + formoterol 4.5 mcg, and placebo, with sample sizes indicated at each time point.*

FDA Label Image

Budesonide Structural Formula (Image 01)

Chemical structure diagram showing steroid and ether components, representing the active ingredients Budesonide and Formoterol Fumarate Dihydrate in Symbicort inhalation aerosol.*

FDA Label Image

Structural Fumarate (Image 02)

Chemical structure of Budesonide and Formoterol Fumarate Dihydrate, the active ingredients in SYMBICORT inhalation aerosol. The image shows the molecular formula including formate and water molecules as part of the dihydrate form.*

FDA Label Image

Figure 1 (Image 03)

An instructional diagram of the SYMBICORT inhaler showing labeled parts including the counter, canister inside, inhaler body, mouthpiece, strap, and mouthpiece cover. The image highlights key components of the aerosol device used for respiratory inhalation.*

FDA Label Image

Figure 2 (Image 04)

An instructional illustration showing hands removing the gray protective cap from a red Symbicort aerosol inhaler. Blue arrows indicate the direction to pull the cap away from the mouthpiece before use.*

FDA Label Image

Figure 3 (Image 05)

An instructional illustration showing a hand holding a Symbicort aerosol inhaler with the mouthpiece pointing left, releasing a spray. The image highlights correct inhaler usage, with the mouthpiece cover removed and held below. It visually demonstrates how to administer a dose from the Symbicort inhaler.*

FDA Label Image

Figure 4 (Image 06)

Illustration showing proper use of a Symbicort aerosol inhaler, where a patient is depicted pressing the inhaler to release medication onto the palm of their opposite hand. The hand-held inhaler device is shown with a protective cap removed, demonstrating the correct technique for administration.*

FDA Label Image

Figure 5 (Image 07)

An instructional illustration showing a person using a Symbicort aerosol inhaler by placing the mouthpiece between their lips and inhaling. The image highlights proper inhalation technique for the respiratory aerosol medication.*

FDA Label Image

Counter (arrow pointing to 80)

An instructional diagram showing a circular dial with numbered markings from 10 to 120, indicating dose count increments for an inhaler device. The dial highlights usage progression, with a pointer near 80 doses remaining.*

FDA Label Image

Counter (arrow pointing to 15)

An illustration of a circular dose counter dial for an inhalation aerosol, marked with numbers from 0 to 120 in increments of 10, used to indicate remaining doses. The pointer is currently near the 30 mark.*

FDA Label Image

Symbicort 160/4.5 Inhalation Aerosol Carton Label 120 Inhalations (Image 16)

Symbicort 160 mcg/4.5 mcg inhalation aerosol label showing budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per dose. The label indicates 120 inhalations per container, for oral inhalation only, prescription use. Manufactured by AstraZeneca Pharmaceuticals LP, with production noted in France. The AstraZeneca logo is visible on the label.*

FDA Label Image

Symbicort 80/4.5 Inhalation Aerosol Carton Label 120 Inhalations (Image 17)

Symbicort 80/4.5 aerosol inhaler label with budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg per inhalation. The label indicates 120 inhalations per container, for oral inhalation only, prescription use. Manufactured for AstraZeneca Pharmaceuticals LP, with production in France. Includes NDC 0186-0372-20 and AstraZeneca branding.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.